The abstract is read at the publisher; the summary is JClub's.
BRIDGE expands human genetic support for therapeutic target–indication pairs, adding 572 pairs and raising coverage from 5.1% to 9.5% in 13,022 phase I+ pairs.
- Why it matters: Direct genetic evidence exists for only a small fraction of clinically investigated target–indication pairs, limiting how broadly human genetics can guide therapeutic target selection.
- What they did: BRIDGE propagates genetic evidence across coupled protein–protein interaction and disease-similarity networks, calibrating candidate scores using randomized substitutions of similarly connected genes lacking direct support.
- The result: In eligible pairs without direct support, 25.3% of network-added pairs reached launch versus 8.6% of remaining candidates (relative success 2.94; 95% CI 2.51–3.45), and at 1,310 selected pairs it captured 265 launched pairs versus 223 with a neighboring-transfer rule.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.